The role of CD36 in cardiovascular disease

Hongyang Shu1,2, Yizhong Peng3, Weijian Hang1,2, Jiali Nie1,2, Ning Zhou4,5,6, and Dao Wen Wang1,2

1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China; 2Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science and Technology, Wuhan 430000, China; 3Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China

Received 20 May 2020; editorial decision 21 October 2020; accepted 29 October 2020; online publish-ahead-of-print 3 November 2020

Abstract

CD36, also known as the scavenger receptor B2, is a multifunctional receptor widely expressed in various organs. CD36 plays a crucial role in the uptake of long-chain fatty acids, the main metabolic substrate in myocardial tissue. The maturation and transportation of CD36 is regulated by post-translational modifications, including phosphorylation, ubiquitination, glycosylation, and palmitoylation. CD36 is decreased in pathological cardiac hypertrophy caused by ischaemia–reperfusion and pressure overload, and increased in diabetic cardiomyopathy and atherosclerosis. Deficiency of CD36 alleviates diabetic cardiomyopathy and atherosclerosis, while overexpression of CD36 eliminates ischaemia–reperfusion damage, together suggesting that CD36 is closely associated with the progression of cardiovascular diseases and may be a new therapeutic target. This review summarizes the regulation and post-translational modifications of CD36 and evaluates its role in cardiovascular diseases and its potential as a therapeutic target.

Keywords

CD36 • Post-translational modification • Diabetic cardiomyopathy • Ischaemia–reperfusion • Cardiac hypertrophy

1. Introduction

CD36 [also known as fatty acid translocase (FAT), glycoprotein lllb (GPlllb), or glycoprotein IV], is a member of the class B2 scavenger receptor family, which includes low-density lipoprotein (LDL), high-density lipoprotein (HDL)-bound scavenger receptor B1, and HDL-bound scavenger receptor B3.1–3 The ligands of CD36 are mainly divided into lipid and protein molecules. The former includes oxidized LDL particles,4 long-chain fatty acids (LCFA),5 phospholipids,6 and others, and the latter includes thrombospondin,7 advanced glycation end products (AGEs),8,9 advanced oxidation protein products (AOPPs),10,11 S100 family proteins (S100-A8, S100-A9, S100-A12),12–14 growth hormone-releasing peptide,15 cell-derived microparticles,16 and amyloid proteins.17

CD36 is expressed in various tissues, including endothelial cells,18 cardiac muscle cells,19 renal tubular epithelial cells,20 liver cells,21 adipocytes,22 platelets,23 and macrophages,24 and is involved in many pathophysiological processes, including immune regulation25 and metabolic regulation.26 For example, CD36 on the cytomembrane of endothelial cells optimizes fatty acid uptake in tissues.18 It also facilitates the uptake of AOPPs in renal tubular epithelial cells, which leads to lipotoxicity and renal tubule interstitial fibrosis in diabetic nephropathy.10 In liver cells CD36 is involved in fatty acid metabolism,27 while on platelets it is related to platelet activation.28 In myocardial tissue, CD36 mediates the uptake of long-chain fatty acids.29 Fatty acids provide over 70% of the adenosine triphosphate (ATP) for myocardial tissue and most of the fatty acids enter the cells through protein-mediated diffusion. Importantly, 70% of this intake is mediated by CD36;29 therefore, CD36 plays an essential role in myocardial lipid metabolism.

The synthesis and translocation of CD36 are affected by many stimuli.30 Short-term stimulation of insulin promotes the translocation of CD36 from the endosome to the cell membrane,31 while long-term stimulation induces protein synthesis.32 Hyperglycaemia and hyperlipidaemia also facilitate the translocation of CD36 to the cell membrane.33 It has been proven that impaired synthesis and abnormal distribution of CD36 shorten myocardial energy supply,34 resulting in the impairment of myocardial contractile function.35 Pressure overload decreases the level of one of the controllers of CD36 synthesis, nuclear receptor peroxisome proliferator-activated receptor a (PPARα).36 Resulting in insufficient myocardial fatty acid uptake and the accumulation of toxic lipids, ultimately leading to heart failure. However, downregulating CD36 in
diabetic cardiomyopathy reduces toxic lipids and improves the contractile function of the heart. Therefore, the influence of CD36 on the myocardium may not be consistent and largely depends on the pathological background.

In this review, we summarize gene polymorphism and post-translational modification of CD36 and focus on its role in cardiovascular diseases, particularly ischaemia/reperfusion, diabetic cardiomyopathy, pathological cardiac hypertrophy, physiological cardiac hypertrophy, and atherosclerosis. We also provide some suggestions for basic and clinical research on CD36, to emphasize the significance of CD36 in the cardiovascular system and shed light on its potential as a therapeutic target.

2. Cd36 gene polymorphism

The human CD36 gene is located on 7q21.11, which has 36 kb and consists of 19 exons with multiple upstream regulatory promoters. Single nucleotide polymorphisms (SNPs) of CD36 are relatively common and have been shown to be closely related to several cardiovascular diseases. The rs1761663 of the CD36 gene has independent effects on body mass index and left ventricular mass. A study conducted among young adult populations in Australia showed that the rs1527479 and rs19844112 of CD36 are related to exercise, heart rate, and lipid oxidation. In the Chinese Han population, the AG genotype of rs1761667 is associated with an increased risk of coronary heart disease (odds ratio 2.337, 95% confidence interval 1.336–4.087; P = 0.003), and the plasma oxLDL level of patients with the AG genotype was significantly higher than that of patients with the GG and AA genotypes. For rs1049673, rs7755, and rs321159 sites, patients with premature coronary heart disease have a family genetic predisposition at high LDL-C levels with GA, AA, and TT genotypes. Four common CD36 SNPs were found (rs1049673, rs7755, rs3211596, and rs3173798) to be significantly associated with extreme lipid profiles in the male Han population in northern China, but no significance was identified in the female population. In addition, rs3211938, which affects susceptibility to malaria, has been shown to resist metabolic syndrome, increase high-density lipoprotein cholesterol, and reduce triglycerides. These genetic studies suggest that CD36 gene polymorphism plays a predictive role in distinguishing cardiac disease risk factors. Therefore, early prevention might be carried out for susceptible people, using CD36 genotyping.

3. Cd36 protein

Human CD36 has a total length of 472 amino acids and a predicted molecular weight of 53 kd, although due to glycosylation, the actual molecular weight is 88 kd. CD36 contains two phosphorylation sites and four palmitoylation sites, which are distributed at the terminals of NH2 and COOH. Two ubiquitination sites are also found at the COOH terminus.

Knowledge of the crystal structure of CD36 remains unclear; but insight into the potential mechanism of FA transport by CD36 can be derived from the recently reported crystal structure of the CD36 family member, lysosomal integral membrane protein-2 (LIMP-2). LIMP-2 is a helical bundle where β-glucocerebrosidase binds, and where ligands are most likely to bind to CD36. The crystal structure also shows the existence of a large cavity that serves as a tunnel through which cholesterol (esters) are delivered from the bound lipoprotein to the outer leaflet of the plasma membrane. CD36 is a double transmembrane protein that cannot form a channel by itself to allow for fatty acids to transfer through to the inside. Interestingly, the outer ring of CD36 contains a large hydrophobic cavity, which provides a docking site for fatty acids and other hydrophobic ligands, facilitating the attraction of hydrophobic ligands to the cell surface, thus promoting the transportation of fatty acids into the cell.

3.1 Cd36 signalling

CD36 is a membrane protein that is synthesized in the polyribosome and then transferred to the endoplasmic reticulum and Golgi apparatus for further processing, and then finally transported by the endosome to the cell membrane. Under the stimulation of insulin or contraction, it moves to the lipid rafts of the cell membrane to facilitate LCFA uptake, which may be associated with the activation of PI3K-Akt and adenosine monophosphate (AMP) kinase (AMPK). CD36 is not only located in plasma membranes and endosomes but is also distributed on mitochondria, although its specific function on mitochondria remains unclear.

The transfer of CD36 from the endosome to the cell membrane surface is mainly regulated by insulin and contraction stimulation, which induces CD36 translocation through different signalling pathways, but finally converges into Rab GTPase proteins AS160 and Rab 8a, accelerating CD36 translocation with the (guanosine triphosphate) GTP/ (guanosine diphosphate) GDP cycle. PI3K in the insulin signalling pathway has been shown to be critical for CD36 translocation, supported by the fact that specific inhibitors of PI3K (Wortmannin and LY-294002) can eliminate CD36 translocation and downregulate LCFA uptake induced by insulin. In addition, among the two downstream effectors of PI3K, PKC-zeta also participates in insulin-induced CD36 translocation, and the other downstream effector, Akt, is involved in the regulation of FOXO1 activity that acts on the CD36 promoter region to regulate CD36 transcription. It is worth mentioning that insulin signalling also promotes the translocation of GLUT4. Under the stimulation of insulin, CD36 and GLUT4 are simultaneously transferred to the sarcolemma, resulting in increased fatty acid and glucose uptake. This is contradictory to the Randle cycle phenomenon, which states that a competitive inhibition exists between free fatty acid (FFA) oxidation and glucose utilization. Further exploration of the time response of GLUT4 and CD36 to different insulin concentrations, and knowledge of the distinction between the vesicle transport pathway and subcellular trafficking will help in understanding this contradictory phenomenon. Recent studies have found that specific family members of vesicle-associated membrane proteins (VAMPs) mediate the intracellular transport of either CD36 or GLUT4. Specifically, VAMP4 translocates CD36 between the mother endosomal compartment and a hypothetical endosomal CD36-specific intermediate compartment, while VAMP5 and VAMP7 mediate GLUT4 homing to intracellular compartments. In particular, the distinct subcellular trafficking of CD36 and GLUT4 has been discussed in detail in a recent review.

Similar to insulin, contraction stimulation promotes the translocation of GLUT4 and CD36 simultaneously. Importantly, contraction stimulation is in an AMPK-dependent manner. It has been confirmed that both 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and oligomycin can induce CD36 translocation by activating AMPK to promote LCFA uptake. Along with various negative feedback mechanisms, AMPK activation-induced CD36 translocation regulates AMPK activity in turn; CD36 forms a protein complex with the AMPK kinase LKB1 and the Src kinase Fyn, and this complex promotes Fyn phosphorylation of LKB1 and its nuclear sequestration, hindering LKB1 activation of AMPK. This
feedback mechanism facilitates the cells to respond appropriately to the outside fatty acid and balance the fatty acid oxidation and uptake.

3.2 Cd36 post-translational modifications

The synthesis, distribution, and function of CD36 are largely affected by its post-transcriptional modification, including ubiquitination, glycosylation, phosphorylation, and palmitoylation. It is worth noting that although there are many acetylation sites on CD36, further research is required to reveal their effect.

3.2.1 Cd36 ubiquitination

Protein ubiquitination is the coupling of protein and ubiquitin, mediated by a ubiquitin ligase (E3).63 CD36 is the target of the E3 ligase, Parkin64 (Figure 1). Differing from the degradation effect of ubiquitination, the monoubiquitylation of CD36 by Parkin enhances its stability and increases its plasma membrane level. In the presence of Parkin,65 LCFA-induced polyubiquitination and degradation of CD36 is significantly down-regulated, likely because one of the ubiquitination sites of LCFA is also the target of Parkin. A recent study confirmed that USP14 is a deubiquitinating enzyme that mediates CD36 deubiquitylation on macrophages. USP14 cleaves ubiquitin chains from ubiquitinated CD36 proteins, thus avoiding the fate of CD36 being transported into the proteasome for degradation66 (Figure 1). However, whether Parkin and USP14 act as E3 ligases and deubiquitinating enzymes in cardiomyocytes remains unclear.

LCFA, a ligand of CD36, significantly enhances the ubiquitination of CD3667 and promotes its degradation after long-term interaction68 (Figure 1). This is a negative factor for the cellular uptake of fatty acids. Recent studies have shown that ubiquitinated CD36 in myocytes stabilizes the structure of insulin receptor substrate 169 and thus maintains insulin signalling. Given that insulin reduces its ubiquitination68 (Figure 1), CD36 may be involved in the self-regulation of the insulin signalling pathway. Moreover, CD36 ubiquitination in macrophages inhibits the formation of atherosclerosis by decreasing fatty acid uptake.70 However, the role of ubiquitinated CD36 in the heart has not yet been elucidated.
3.2.2 Cd36 glycosylation
The glycosylation of CD36 is N-linked at asparagine residues (Asn) mediated by glycosyltransferase.\(^{51,72}\) There are 10 glycosylation modification sites of CD36 in humans, located in the extracellular segment of CD36.\(^{73}\)

Apart from increasing the molecular weight of CD36, glycosylation could also stabilize the tertiary folding of polypeptides and is therefore essential for forming the spatial structure of CD36.\(^{74}\) It affects the folding of CD36, thus influencing its correct translocation to the cell membrane. It has been proven that carboxyl-terminal sites Asn247, Asn321, and Asn417 are indispensable for CD36 trafficking.\(^{71}\) Mutations in Asn108 and Asn173 sites result in the abnormal distribution of CD36 on the COS m6 cell membrane.\(^{73}\) Mutations in Asn 102 of CD36 have been found in spontaneously hypertensive rats (SHRs).\(^{75}\) Since Asn102 is located in the fatty acid-binding pocket, mutations at this glycosylation site may have a greater potential to affect fatty acid docking in the CD36 pocket, thereby affecting fatty acid transport. CD36 protein levels in SHR are significantly down-regulated and fatty acid intake is reduced, which may be related to the glycosylation mutation of Asn102. However, the role of Asn102 in SHRs has not yet been confirmed experimentally. Further research is required to clarify the role of Asn102 and other glycosylation sites in cardiovascular diseases.

3.2.3 Cd36 phosphorylation
CD36 has two phosphorylation sites, Thr92 and Ser237, phosphorylated by protein kinase C (PKC)\(^{76}\) and protein kinase A (PKA),\(^{77}\) respectively (Figure 1). CD36 in small intestinal epithelial cells is dephosphorylated by intestinal alkaline phosphatase (IAP)\(^{78}\) (Figure 1). In platelets, phosphorylation of Thr92 mediates the binding of CD36 and thrombospondin.\(^{79}\) Phosphorylation of CD36 at Thr92 is also necessary for the adhesion of plasmodium falciparum-infected erythrocytes to human dermal microvascular endothelial cells under flow condition.\(^{80}\) CD36 phosphorylated at Ser237 downregulates the fatty acid uptake rate of platelets and enterocytes.\(^{78,81}\) However, in vitro studies are insufficient to validate the in vivo findings of CD36 phosphorylation.

3.2.4 Cd36 palmitoylation
Most members of the DHHC (Asp–His–His–Cys) family of proteins have palmitoyl transferase activity, and these members are confirmed to include the main palmitoyl acyl transferases (PATs).\(^{82}\) DHHC4/5 have been shown to be the PATs of CD36 in adipocytes (Figure 1). The absence of either DHHC4 or DHHC5 prevents palmitoylation and the insertion of CD36 on the adipose membrane, thereby destroying the CD36-dependent fatty acid uptake.\(^{83}\) Selenoprotein K (SelK),\(^{84}\) which is neither a PAT nor a palmitoyl-protein thioesterase (PPT), is also required for palmitoylation of CD36 in macrophages, suggesting that other proteins may also be involved in the palmitoylation of CD36.

CD36 has four palmitoylation sites: Cys3, Cys7, Cys464, and Cys466 (Figure 1). Palmitoylation is strengthened by insulin stimulation. Combined mutations of these four palmitoylation sites hinder CD36 translocation to the cell membrane for fatty acid uptake, even in the presence of insulin and AMPK.\(^{85}\) With the inhibition of CD36 palmitoylation by ceruloplasmin,\(^{86}\) a palmitoylation-specific inhibitor, the processing of CD36 at the endoplasmic reticulum and transport through the secretory pathway extends from 90 min to 4 h in melanoma cells, indicating that palmitoylation is essential for the transport and translocation of CD36.

Increased palmitoylation of CD36 is found in liver steatosis and fibrosis.\(^{27}\) The decrease in CD36 palmitoylation downregulates the uptake of fatty acids and helps to balance the fatty acid metabolism in the liver cells, thus eliminating liver steatosis and fibrosis.\(^{27}\) However, no research has revealed the effects of the palmitoylation of CD36 in the cardiovascular system.

4. Cd36 and cardiovascular diseases

4.1 Cd36 and ischaemia/reperfusion
Ischaemia/reperfusion is characterized by the abrupt interruption, followed by the subsequent restoration, of blood flow.\(^{87}\) The cut-off of oxygen and nutrition results in various metabolic changes,\(^{88}\) including alterations in lipid metabolism. The change of CD36 in ischaemia/reperfusion has been shown by using (3) H-labelled metabolic substrates to measure the metabolic changes in Wistar rat hearts at different stages during ischaemia/reperfusion.\(^{89}\) During ischaemia, CD36 of the sarcolemma is down-regulated by 32%, and the fatty acid oxidation rate decreases by 95%. In the reperfusion stage, CD36 levels remained low, but the fatty acid oxidation rate returned to the pre-ischaemic state.\(^{89}\) The increased pH of the endosome may contribute to the low level of CD36 throughout the whole ischaemia/reperfusion period.\(^{90}\) The translocation of CD36 to the sarcolemma is significantly enhanced when the pH of the endosome is high, while a decrease in pH inhibits this translocation. During ischaemia, myocardial glycolysis increased by 86% and lactic acid level increased by seven-fold (Figure 2), leading to a low pH state and subsequently suppressed CD36 translocation. When shifting to the reperfusion phase, the lactic acid in cardiomyocytes could not be effectively eliminated in a short period; the cells may still be at a low pH, and CD36 translocation is still suppressed (Figure 2).

At the same oxygen consumption level, glucose provides more energy than lipids, so it is the preferred choice for maintaining myocardial function.\(^{91,92}\) The reduction of CD36 is beneficial to the conversion of the metabolic substrates from fatty acids to glucose during hypoxia. The consistently low level of CD36 may help cardiomyocytes to maintain energy balance (Figure 2). Moreover, the rate of fatty acid oxidation in cardiomyocytes in ischaemia is reduced to 5% of basal states,\(^{89}\) and a relatively low CD36 prevents the accumulation of triglycerides in the cytosol by reducing the absorption of fatty acids (Figure 2). High concentrations of fatty acids in cardiomyocytes reduce the recovery of ischaemic heart function during the reperfusion stage by triggering insulin resistance and cardiomyocyte apoptosis.\(^{93-95}\) Therefore, the reduction of CD36 during ischaemia benefits the heart by avoiding the excessive accumulation of triglycerides, and a CD36 decrease during ischaemia is a favourable adaptation for cardiomyocytes to survive.

The left ventricle undergoes a wound healing response after myocardial infarction,\(^{96}\) including a strong infiltration of macrophages that promote the removal of dead cells and the renewal of extracellular matrix.\(^{97}\) Contrary to the effects of a decrease in CD36, which is beneficial to the energy production and survival of cardiomyocytes, the reduction of CD36 in macrophages has been proven to be detrimental to the repair stage after myocardial infarction. The lack of CD36 leads to a reduction in the phagocytic receptor (myeloid-epithelial-reproductive-tyrosine kinase, Mertk) and nuclear receptor (nuclear receptor subfamily 4, group A, member 1, Nr4a1),\(^{98}\) which affects the phagocytic function of cardiac macrophages, and exacerbates heart rupture caused by myocardial ischaemia.\(^{99}\) CD36 blockers inhibit phagocytosis of macrophages and restrain cardiac remodelling after myocardial infarction.\(^{99}\) In addition,
Platelet factor 4 (PF4) reduces the phagocytic function of macrophages and leads to higher mortality from myocardial infarction, which is also attributed to CD36 signalling down-regulation. Therefore, the decrease of CD36 or its dysfunction in macrophages deteriorates myocardial infarction. Although CD36 is more abundantly expressed in endothelial cells than in cardiomyocytes, the role of endothelial CD36 in ischaemic cardiomyopathy remains unclear.

Although reducing the content of CD36 has contradictory effects on macrophages and cardiomyocytes, current treatments for ischaemia–reperfusion still focus on inhibiting the function of CD36. The likely reason is that there are significantly more cardiomyocytes than macrophages in myocardial tissue, and the improvement of cardiomyocyte function by inhibiting CD36 may exceed the harm caused by macrophages. For example, Mansor et al. corrected post-hypoxia/reoxygenation cardiac metabolic disorders by injecting sulfo-N-succinimide oleate (a CD36-specific inhibitor that results in an arrest of the FFA transport) into the hearts of type 2 diabetic male Wistar rats 4 min before hypoxia. Pre-injection of selective CD36 ligand EP 80317 (a synthetic hexapeptide growth hormone-releasing peptide family analogue that is devoid of somatotroph activity and azapeptide CP-3(iv) in mice significantly reduced the myocardial infarct size. Exenatide, a small-molecule drug that regulates glucose metabolism, has also been shown to improve cardiac function after cardiac ischaemia–reperfusion injury by inhibiting the translocation of CD36.

Drug studies provide strong evidence that inhibiting the function of CD36 contributes to the recovery of heart function, but the most direct evidence comes from heart CD36-knockout (cCD36KO) mice. Inducible cardiomyocyte-specific CD36 ablation does not alter cardiac morphology but improves functional recovery after ischaemia/reperfusion. The decrease in fatty acid oxidation rate caused by the decrease in CD36 lays the foundation for increasing the rate of glucose oxidation. It has been shown that this recovery is due to the lower hydrogen ion concentration resulting from the uncoupling of glycolysis from glucose oxidation produced before and after ischaemia. However, CD36 systemic knockout mice still suffer from severe ischaemia–reperfusion injury; presumably, this relates to the general reduction of CD36. Not restricted to the heart, systemic metabolic changes occur in a vast number of tissues in the systemic knockout mice, and due to various potential adaptive adjustments from the embryonic stage, these mice may be significantly different from heart-specific knockout mice.

However, some studies on ischaemia/reperfusion in spontaneously hypertensive rats have challenged the protective effect of a decline in CD36 in cardiovascular diseases.
CD36. Instead of the inhibition of CD36, the overexpression of CD36 in SHRs reduced the infarct size, but the underlying mechanism has not been clarified. Given that the model already has a pathological factor of hypertension, it is possible that the overexpression of CD36 reduces the myocardial injury risk brought by hypertension and indirectly protects the infarcted myocardium caused by ischaemia/reperfusion.111

4.2 Cd36 and diabetic cardiomyopathy
The typical characteristics of diabetic cardiomyopathy are altered lipid metabolism and impaired insulin signalling pathways.112–114 Without any pathological stimulus, CD36 on the cardiac sarcolemma is significantly increased in obese Zucker rats,115 db/db. mice,116 and high-fat-fed rats.117 The up-regulation of CD36 has also been confirmed in the cardiomyocytes of patients with diabetic cardiomyopathy.118

The increase in CD36 expression in the sarcolemma in diabetic cardiomyopathy may be attributed to hyperinsulinaemia, hyperglycaemia, and hyperlipidaemia. Prior to insulin resistance, CD36 translocates from endosomes to the myometrium because of the alkalinization of endosomes, which is caused by lipid-related inhibition of the proton pumping activity of vacuolar-type H+-ATPase (v-ATPase).30,119 In the early stages of diabetes, insulin is at high levels.120 Luiken et al. found that insulin stimulation in isolated myocardial rat cells resulted in a 1.5-fold increase in CD36 on the sarcolemma and a 62% decrease in intracellular CD36, suggesting that insulin could effectively promote the translocation of CD3631 (Figure 3). Chronic insulin stimulation also induces CD36 mRNA translation by activating the transcription factor forkhead box O1 (FOXO1), which further facilitates CD36 protein synthesis121 (Figure 3). In the late stage of diabetes, the insulin level has decreased significantly, and the cardiomyocytes are resistant to insulin, but CD36 has been permanently transferred to the myometrium during the early stage.117 The decline of insulin does not change the fact that a large number of fatty acids have already been taken into cardiomyocytes. Similar to chronic insulin stimulation, high glucose stimulation increases CD36 mRNA translation,122 followed by increased CD36 expression, and membrane translocation of CD36 by palmitic acid stimulation.33 In the advanced stage of diabetes, hyperglycaemia and hypertriglyceridaemia may occur, thus further promoting CD36 expression and increasing its membrane distribution.123 In addition to external factors such as insulin, glucose, and lipids, the latest research suggests that the increase in CD36 in diabetic cardiomyopathy is also associated with the regulation of microRNA. MiR-320, which acts as a small activating RNA in the nucleus, is highly expressed in mice with diabetic cardiomyopathy and promotes CD36 expression by directly acting on its nuclear transcription124 (Figure 3). In contrast, miR-200b-3p is remarkably reduced in diabetic cardiomyopathy, which is an effective inhibitor of CD36 (Figure 3).

CD36 increases during diabetic cardiomyopathy, which in turn worsens heart function.125 The increased distribution of CD36 on the myometrium results in the intake of a large amount of fatty acids. Fatty acids...
in the cytoplasm could activate peroxisome proliferator-activated receptors (PPARs), thereby inducing the up-regulation of enzymes necessary for mitochondrial β-oxidation, leading to a significant increase in fatty acid oxidation rates. However, the rate of fatty acid uptake and storage is higher than the rate of oxidation, resulting in the accumulation of lipids in the cell (Figure 3). Excessive lipid intermediates, including diacylglycerol and ceramide, have been shown to induce insulin resistance and trigger myocardial contractile dysfunction. At the same time, high levels of β-oxidation of fatty acids produce a large amount of reactive oxygen species (ROS), which can also induce inflammation and insulin resistance which aggravates myocardial contractile dysfunction (Figure 3). Lipids could directly lead to contractile dysfunction by promoting myocardial cell apoptosis. Therefore, inhibiting the uptake of long-chain fatty acids by targeting CD36 is the preferred strategy to reduce cardiac insulin resistance and ultimately prevent diabetic heart failure.

A fatty acid–glucose balance is essential for maintaining normal cardiac function. The heart operes optimally when it uses a mixture of energy-providing substrates, especially in terms of fatty acids and glucose. The preferential use of a single type of substrate impairs the flexibility of metabolism, limits auxiliary metabolic pathways, and affects the correct post-translational modification of putative proteins (particularly the transcriptional factors, such as PGC-1α and PPARα) thereby impairing heart function. In diabetic cardiomyopathy, the metabolic substrate of the myocardium shifts to fatty acids. Cardiomyocytes are insufficiently equipped to store large amounts of lipids with accumulated acylglycerols and ceramides, causing cellular damage by lipotoxicity and insulin resistance. Meanwhile, weakened glucose metabolism leads to an insufficient substrate supply of the pentose phosphate pathway and hexosamine biosynthetic pathway, resulting in impaired auxiliary metabolism. Therefore, inhibiting myocardial fatty acid metabolism helps to reduce lipotoxicity and maintain the fatty acid–glucose balance, thereby improving diabetic cardiomyopathy.

Several studies have shown that reducing the distribution of CD36 on the sarcolemma, thereby inhibiting the uptake of LCFAs, helps to improve the heart function of diabetic cardiomyopathy. For example, mice overexpressing myosin heavy chain (MHC)-PPARα show severe cardiomyocyte lipid accumulation and cardiac dysfunction. However, due to the lack of CD36, the offspring produced by crossing MHC-PPARα mice with CD36-deficient mice (MHC-PPARα/CD36−/− mice) had decreased triglyceride accumulation and cardiac dysfunction under basic conditions and on a high-fat diet. Glucagon-like peptide-1 could eliminate the lipotoxicity of diabetic cardiomyopathy by stimulating protein kinase A (PKA) inhibition of the CD36 pathway. Exogenous H2S protects diabetic hearts by inhibiting the translocation of CD36. N-Acetylcysteine also restored Sevo-postC cardioprotection in diabetes by reducing Foxo1 and CD36. Fibroblast growth factor 21 (FGF21) deletion aggravates cardiac lipid accumulation by upregulating cardiac Nrf2-driven CD36 expression; therefore, FGF21 is a potential agent for the reduction of lipid accumulation as it ameliorates diabetic cardiomyopathy by downregulating the expression of CD36.

4.3 Cd36 and cardiac hypertrophy

4.3.1 Cd36 in hereditary hypertrophic cardiomyopathy

Hereditary hypertrophic cardiomyopathy (HCM) is a disease whose main pathological manifestation is cardiac hypertrophy, and it is caused by a dominant mutation in the gene encoding the cardiac sarcomeric protein. A survey of CD36 and hereditary hypertrophic cardiomyopathy patients showed that 37.9% of HCM patients with asymmetric ventricular septal hypertrophy had a loss of CD36 protein, which is accompanied by defective myocardial long-chain fatty acid intake, suggesting that the reduced CD36 may play a role in the pathogenesis of hereditary hypertrophy. The relationship between CD36 translocation and left ventricular contractile dysfunction has been verified in HCM mice. Owing to the decrease in CD36 translocation to the plasma membrane, ATP and triglycerides in the myocardium dramatically decline. Although the mechanism by which CD36 decreases in hereditary hypertrophic cardiomyopathy remains to be investigated, increasing CD36 and improving fatty acid intake may provide a new solution for the treatment of hereditary hypertrophic cardiomyopathy.

4.3.2 Cd36 in pathological/physiological cardiac hypertrophy

Differing from hereditary hypertrophic cardiomyopathy generated by genetic mutations, secondary cardiac hypertrophy is mainly caused by external stress, including pressure overload or physical exercise. It is naturally divided into physiological cardiac hypertrophy and pathological cardiac hypertrophy according to different stimulus factors and outcomes. Changes in CD36 in two different types of hypertrophic hearts were first demonstrated in 2013. Exercise training significantly increased the expression of CD36 in the heart, but pressure overload reduced the expression of CD36. The decrease in CD36 in pathological cardiac hypertrophy and the up-regulation in physiological cardiac hypertrophy may be related to PPARα and peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α). Physical exercise increases the expression of PPARα and PGC1α in the heart, while cardiac pressure overload reduces them (Figure 4). The promoter region of CD36 contains PPARα response elements. It has been shown that the nuclear receptor PPARα and nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) regulate CD36 expression in macrophages and cardiac microvascular endothelial cells.

As mentioned before, when myocardial cells are facing a crisis of ischemia and hypoxia, metabolism is remodelled. As for hypoxic pathological cardiac hypertrophy, early and timely reduction of the distribution of CD36 on the cell membrane helps to eliminate the injury caused by a subsequent large intake of fatty acids. The reduction of CD36 not only promotes the substrate transition of fatty acids to glucose but also eliminates the accumulation of toxic lipid intermediates. However, the reduction of CD36 may ultimately shorten the energy supply in the chronic stage of pathological cardiac hypertrophy. Although the glycolytic pathway of glucose is enhanced in maladaptive pathological cardiac hypertrophy due to the inhibition of fatty acid metabolism, by elevated phosphofructokinase and lactate dehydrogenase levels, glycolysis and energy generated from other substrates (lactic acid, branched-chain amino acids, and ketone bodies) could not compensate for the reduction of fatty acid oxidation, putting the heart in an insufficient cardiac energy state (Figure 4). Although the reduction of CD36 leads to a remarkable decline in the overall intake of fatty acids, studies have shown that fat synthesis-related enzymes, including sterol-responsive element-binding protein-1c (SREBP-1c), stearoyl-CoA desaturase 1 (SCD1), stearoyl-CoA desaturase 2 (SCD2), and glycerol-3-phosphate acyltransferase (GPAT), are not down-regulated in pathological cardiac hypertrophic cardiomyocytes (Figure 4). However, the activity and content of hormone-sensitive lipase (HSL) and diacylglycerol lipase (DAGL) that break down fat both decrease, resulting in a 31% increase in triglycerides and a 200% increase in diacylglycerol in myocardial...
Insulin resistance caused by accumulated toxic lipids further exacerbates the lack of energy supply in the heart. In addition, pressure overload-induced cardiac hypertrophy leads to an excessive metabolic shift from fatty acid to glucose. As mentioned before, the aberrant preference to one substrate would cripple the metabolic flexibility and cardiac contractility. Fatty acid metabolism needs to be strengthened in order to restore the balance of fatty acid and glucose and improve cardiac metabolism. In other words, heart function will worsen if CD36 is excessively down-regulated.

Recent studies on CD36 cardiac-specific knockout mice and systemic knockout mice have demonstrated the role of CD36 in pathological cardiac hypertrophy. CD36 cardiac-specific knockout mice rapidly transferred from compensatory cardiac hypertrophy to heart failure due to an imbalance of energy. Comparatively, CD36 systemic knockout mice, when compared to wild-type mice, show pronounced myocardial interstitial fibrosis, cardiac enlargement, and contractile dysfunction after transverse aortic constriction (TAC) surgery. The myocardium of CD36KO-TAC leads to insufficient energy supply not only due to the decrease of CD36 but also because of the increase of de novo amino acid synthesis from glucose, which further reduces the size of the high-energy phosphate pool. However, whether overexpression of CD36 relieves the energy deficiency in pathological cardiac hypertrophy, and thereby stops the heart failure caused by cardiac pressure overload needs further investigation. It is certain that increasing the supply of fatty acids in myocardial cells to expand the high-energy phosphate pool is beneficial for hypertrophic myocardium. Even in the case of a decrease in medium-chain acetyl-CoA dehydrogenase, providing medium-chain fatty acids for cardiomyocytes lacking CD36 and bypassing long-chain fatty acids can still relieve cardiac pressure overload-induced heart failure.

### 4.4 Cd36 and atherosclerosis

Atherosclerosis is a progressive chronic inflammation of the arterial wall, manifested by the accumulation of foam cells, retention of macrophages in plaques, and thrombosis. CD36 expression in macrophages is significantly increased in human carotid atherosclerotic tissue, particularly in advanced atherosclerosis. In diet-induced mouse atherosclerosis models and in vitro atherosclerosis models, CD36 on macrophages was also remarkably elevated.
The main cause of foam cell generation is the excessive influx of modified low-density lipoproteins (LDL), and the accumulation of cholesterol esters in intimal macrophages. As an important scavenger receptor in macrophages, CD36 plays a critical role in cellular oxLDL accumulation and foam cell formation. Macrophages bind with and internalize oxLDL via CD36 due to their high-affinity CD36-oxLDL. Along with the internalization of the CD36-oxLDL assembly, oxLDL enters the cell and accumulates, to transfer the macrophages into the foam cells. OxLDL also provides putative oxidized lipids as ligands for the transcription factor PPAR-γ, which is the main transcription factor of CD36, thereby activating CD36 gene expression to further increase the uptake of oxLDL. The uptake of oxLDL by CD36 triggers a chain reaction and creates a cycle, putting CD36 in the centre of foam cell formation.

Many pathogenic factors that lead to atherosclerosis are involved in the regulation of CD36. Smoking and hyperglycaemia are risk factors for atherosclerosis, nicotine promotes the expression of CD36 in macrophages in a PPAR-γ dependent manner, and hyperglycaemia results in high CD36 mRNA translation efficiency, which increases the expression of CD36. Premature atherosclerotic cardiovascular disease is a common destructive complication of systemic lupus erythematosus (SLE), which may be related to elevated CD36 expression, for reasons currently unknown. IL-34, a cytokine associated with various inflammations and autoimmune diseases, also increases the expression of CD36 via the p38 MAPK signalling pathway to promote the formation of foam cells, and thus is a potential biomarker of atherosclerosis. CCN3 (Cyr61, CTGF, Nov) is an important regulator of vascular homeostasis. The lack of CCN3 leads to the increased formation of foam cells, which is attributed to the increased expression of CD36, possibly due to the elevated level of CCN1 protein. Thrombin also promotes the formation of atherosclerosis by regulating protein kinase C0 dependent activating transcription factor 2-mediated CD36 expression. Retinoic acid binding protein 4 (RBP4), an adipokine that plays a decisive role in glucose metabolism and insulin sensitivity, has been shown to promote atherosclerosis by upregulating CD36 expression. The method is dependent on the Jun N-terminal kinase signal transducer and activator of transcription 1, and activation of CD36-mediated cholesterol uptake to facilitate the formation of foam cells.

In addition to the formation of foam cells, CD36 is also involved in the inflammatory response of macrophages. For example, targeting CD36 inhibits the NLRP3 inflammasome, resulting in a decrease in serum IL-1β in atherosclerotic mice. CD36-related uptake of oxLDL induces the specific expression profile of macrophage oxidative stress markers (5-epi-5-F2t-IsoP, 15-Et1-IsoP, 8-F3t-IsoP, and 15-keto-15-F2t-IsoP) and inflammation markers (PGDM, 17-trans-PGF2α, and 11β-PGF2α). Even relatively low concentrations of oxLDL can induce a durable atherogenic macrophage phenotype through epigenetic histone modification. In addition, CD36 was recently found to drive the chronic inflammatory response of macrophages by reprogramming mitochondrial metabolism.

Generally, the acute inflammatory response gradually subsides, as the infiltrating immune cells gradually migrate to the draining lymph nodes. However, inflammation in atherosclerosis does not spontaneously subside. Macrophages, with a pro-inflammatory phenotype, are trapped in the atherosclerotic plaque, causing a continuous inflammatory response. The oxLDL/CD36 interaction is essential for the retention of macrophages in plaques. The migration chemokines, CCL19 and CCL21, largely decrease in macrophages after oxLDL stimulation, with persistent expression of CD146 that promotes macrophage retention in plaques. Importantly, the migration of CD36 null macrophages is not inhibited by oxLDL, compared with wild-type macrophages, underscoring the importance of CD36 signalling in macrophage retention. Two mechanisms may explain oxLDL/CD36 signal-related macrophage retention. Firstly, oxLDL-mediated CD36 signal transduction results in the continuous activation of focal adhesion kinase and the inactivation of Src homology 2 containing phosphotyrosine phosphatase, which leads to disorders of cytoskeleton assembly and disassembly, and the loss of macrophage activity. Secondly, oxLDL can also induce the loss of macrophage polarity by activating the Vav/Rac pathway and inactivating the non-muscle myosin II. In addition to oxLDL stimulation, CD36 also mediates the inhibitory effect of advanced glycation end product [Nε-carboxymethyllysine (CML)] on the retention of macrophages. CD36 is activated by CML and triggers the production of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-derived ROS, which then promotes F-actin polymerization to inhibit the migration of macrophages and accelerate the development of atherosclerosis in diabetic patients.

CD36 is a glycoprotein with a high expression level in platelets and is closely related to the formation of the prethrombotic phenotype in the high-fat state. Accumulating evidence has shown that there is a high correlation between the platelet activation response to oxLDL and the expression level of CD36. CD36 null subjects have slow thrombosis, while elevated platelet CD36 expression may increase the risk of thromboembolism. Animal experiments showed that the deletion of the CD36 gene protects mice from the increased platelet reactivity associated with hyperlipidaemia and the accompanying thrombotic phenotype. OxLDL-mediated CD36 signal transduction can activate platelets in a variety of ways. Firstly, after CD36 is activated, it recruits Src family kinases Fyn and Lyn, and further promotes the activation of non-receptor tyrosine kinases Syk and (c-Jun-N-terminal kinase) JNK, leading to the exposure of P-selectin and activated integrin, thereby enhancing thrombosis. Secondly, oxLDL stimulates the continuous generation of NOX2-derived ROS through the CD36-PKC pathway and promotes platelet hyperfunction by regulating cGMP signal transduction. Thirdly, in response to the signal of oxLDL/CD36, the activated protein kinase ERK5 promotes the exposure of procoagulant phosphatidylinerine (PS) on the platelet surface, thereby causing platelet activation and aggregation. Meanwhile, CD36 also activates platelets through the interaction with endothelial cell-derived microparticles oxPL, which makes platelets more sensitive to low concentrations of agonists. Lastly, advanced glycosylation products (AGEs) in diabetic patients also serve as ligands to bind to platelet CD36, leading to platelet hyperreactivity and inducing a prethrombotic phenotype.

In view of the important role of CD36 in promoting atherosclerosis, anti-atherosclerotic drugs mainly focus on reducing the expression of CD36. Traditional Chinese medicine, including salvianolic acid B (a hydrophilic component derived from the herbal salvia miltiorrhiza), andrographolide (the biologically active component of Andrographis paniculata), and scopolamine (plant flavonoids), all suppress the development of atherosclerosis by lowering the expression of CD36. Tamoxifen, an anti-breast cancer drug, has also been confirmed to inhibit the expression of CD36 by inhibiting the PPAR-γ signalling pathway, thereby combating atherosclerosis. The apoA-I mimetic peptide D4F can also reduce the formation of macrophage-derived foam cells by inhibiting the expression of CD36. The new members of the calcitonin gene-related peptide family intermedin and C1q/tumour necrosis factor-related protein 13 (C1R13) inhibit the formation of macrophage foam cells and reduce atherosclerosis plaques by promoting the degradation of CD36 mRNA and promoting autophagolysosomal-dependent...
CD36 degradation, respectively. vasostatin-1 is a chromogranin A (Cga)-derived peptide (76 amino acids) that can inhibit vasoconstriction and angiogenesis. Its inhibitory effect on atherosclerosis is also associated with the down-regulation of CD36. Currently, researchers are studying the nanoparticles targeting CD36 specifically to enhance efficacy and reduce side effects.

5. Conclusion and perspective

Cardiovascular diseases have been seriously endangering the physical and mental health of older adults, and they are particularly prominent with the current increase in the aging population. Cardiac lipid metabolism remodelling plays a key role in cardiovascular system diseases such as ischaemia–reperfusion, diabetic cardiomyopathy, and cardiac hypertrophy. CD36 is a vital molecule in lipid metabolism. Changes in its synthesis, localization, and function directly affect the energy supply and metabolism of the heart. Studies on CD36 in different diseases suggest that CD36 may be potentially useful for treatment. Therefore, translational activation, post-translational modification, and localization changes of CD36 may provide new directions for the treatment of cardiovascular diseases.

Post-translational modifications of CD36 have been studied for nearly 30 years. Post-translational modifications, including phosphorylation, ubiquitination, palmitoylation, and glycosylation, accurately regulate the maturation, transport, and positioning of CD36. In vitro research has revealed the impact of post-translational modification of CD36 on cellular fatty acid uptake in adipocytes and muscle cells. However, few studies have demonstrated its importance in cardiovascular systems. Whether these modifications of CD36 alter the cellular uptake of fatty acids in the myocardium and further influence cardiac function still remains to be elucidated. Determining which enzymes mediate these modifications in cardiomyocytes and whether these enzymes are useful as new therapeutic targets, requires further investigation.

Fatty acids may also cause excessive lipid accumulation while providing energy. The increase in fatty acid uptake caused by CD36 can be beneficial or harmful under different pathological conditions. Fatty acids in cells are modulated by CD36 and are also affected by the rates of mitochondrial aerobic oxidation, and triglyceride synthesis and decomposition. Therefore, to evaluate the role of CD36 in myocardial lipid metabolism, the corresponding mitochondrial aerobic oxidation and triglyceride synthesis also needs to be taken into consideration. Since it is not uncommon that more than two pathological factors are combined at the same time, such as hypertension and myocardial infarction in diabetes, the impact of CD36 on myocardial lipid metabolism and cardiac function is definitely more complicated when that occurs. Therefore, further research is needed to investigate these situations.

The function of CD36 in regulating lipid metabolism in cardiomyocytes is not limited to lipid uptake. CD36 in mitochondria increases in parallel with the up-regulation of FA oxidation, and recent studies have shown that CD36 mediates a mitochondrial metabolic switch from oxidative phosphorylation to superoxide production in response to its ligand, oxidized LDL. Moreover, mitochondrial-specific inhibition of superoxide inhibited oxidized LDL-induced nuclear factor-κB (NF-κB) activation and inflammatory cytokine generation. In addition, CD36 also forms complexes with certain metabolic molecules and participates in the energy regulation process through direct interactions. For example, CD36 regulates the activity of AMPK by forming a molecular complex with Lyn and LKB1 and inhibits the activation of LKB1, which is a known AMPK agonist. Further study on the function of CD36 beyond myocardial lipid uptake will help to provide a more comprehensive understanding of myocardial lipid metabolism dysfunction and related cardiovascular complications.

In response to insulin and contraction stimulation, both CD36 and GLUT4 translocate to the sarcolemma to increase fatty acid and glucose uptake, respectively, which is contradictory to the Randle cycle phenomenon. How to specifically regulate CD36, without affecting the recycling of subcellular GLUT4, is also an area that remains to be determined. Previous studies have focused on the related proteins in the GLUT4 and CD36 vesicle transport pathways. For example, VAMP4 mainly mediates vesicle transport of CD36, while VAMP5 and VAMP7 are involved in GLUT4 vesicle transport. These studies on the subcellular transport of CD36 and GLUT4 help explain and distinguish the different energy regulation patterns made by cardiomyocytes in the face of different signal stimuli.

In the cardiovascular system, CD36 is not only expressed on the surface of cardiomyocytes but also exists in other cells, such as endothelial cells. Although a large number of studies have reported that the CD36 of endothelial cells is critically involved in the progression of vascular diseases such as atherosclerosis, little research has been performed to explore its effect on diabetic cardiomyopathy, hypertrophic cardiomyopathy, and other diseases. Therefore, an in-depth study of the effects of CD36 on myocardial metabolism in other types of cells is also an important issue. In addition, in view of the universality of CD36 expression, drugs developed for targeting CD36 should specify cell populations and CD36 sites to limit side effects, avoid the potential for off-target effects, and improve their efficacy.

Data accessibility
Most of the 207 references are accessible in pubmed.

Conflict of interest: none declared.

Funding
This work was supported by the National Science Foundation of China (81570261,82070316), Cardiovascular Health Alliance of China-Advanced Fund (2019-CCA-ACCESS-059).

References

1. Luiken JJFP, Chanda D, Nabben M, Neumann D, Glatz JFC. Post-translational modifications of CD36 (SR-B2): Implications for regulation of myocellular fatty acid uptake. Biochim Biophys Acta 2016;1862:2253–2258.
2. Brinkmann JF, Abunrad NA, Ibrahim A, van der Vusse GJ, Glatz JFC. New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem J 2002;367:561–570.
3. Kronenberg A, Grahl H, Kehrel B. Human platelet CD36 (GPIIIb, GPIV) binds to cholesterol-hemisuccinate and can be purified by a simple two-step method making use of this property. Thromb Haemost 1998;79:1021–1024.
4. Jay AG, Chen AN, Paz MA, Hung JP, Hamilton JA. CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependant upon fatty acid binding. J Biol Chem 2015;290:4590–4603.
5. Liu J, Yang P, Zuo G, He S, Tan W, Zhang X, Su C, Zhao L, Wei L, Chen Y, Ruan X, Chen Y. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress. Lipids Health Dis 2018;17:153.
6. Lee S, Eguchi A, Sakamoto K, Masumura S, Tsuchi K, Inoue K, Masuda D, Yamashita S, Fushiki T. A role of CD36 in the perception of an oxidised phospholipid species in mice. Biochem Biophys Acta 2015;36:303–311.
7. Simantov R, Febbraio M, Silverstein RL. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 2005;24:27–34.
CD36 in cardiovascular diseases

2. Zhou W, L W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012;119:613-614.

3. Ohgami N, Nagi R, Ikemoto M, Araki H, Kuniyasu A, Horisuci H, Nakayama H. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2006;1070:350-355.

4. Li X, Zhang T, Geng J, Wu Z, Xu L, Liu J, Tian J, Zhou N, Nie J, Bai X. Advanced oxidation protein products promote lipotoxicity and tubulointerstitial fibrosis via CD36/β-Catenin pathway in diabetic nephropathy. Antioxid Redox Signal 2019;31:521-538.

5. Iwao Y, Nakajou K, Nagi R, Kitamura K, Anraku M, Maruyama T, Otagi M. CD36 is an important receptor promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008;295:F1871-80.

6. Kerkhoff C, Sorg C, Tandon NN, Nacken W. Interaction of S100A8/S100A9-arachidonic acid complex with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry 2001;40:241-248.

7. Kawano T, Shimamura M, Nakagami H, Iso T, Koriyama H, Takeda S, Baba K, Sasaki T, Sakaguchi M, Morishita R, Mochizuki H. Therapeutic vaccine against S100A9 (100 calcium-binding protein A9) inhibits thrombosis without increasing the risk of bleeding in ischemic stroke in mice. Hypertension (Dallas, TX 1979) 2017;7:1335-1346.

8. Farshadzadeh J, Mangilian Shahrababki P, Bagher V. S00A12 CD36: a novel player in the pathogenesis of atherosclerosis! Cytokine 2019;122:154104.

9. Bodar V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Shiyun D, Zhao Y, Liu N, Sun X, Yang M, Kholmukhamedov A, Schulte ML, Cooley BC, Scoggins NO, Wood JP, Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Biochim Biophys Acta 2018;1861:921-937.

10. Glatz JFC, Nabben M, Heeschen C, Zandvoort MAMJ, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JFC. Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure. Am J Physiol Heart Circ Physiol 2017;312:H552-H560.

11. Abdurrah NA, Goldberg JJ. CD36 actions in the heart: lipids, calcium, inflammation, repair, and more! Biochim Biophys Acta 2016;1861:1442-1449.

12. Dobrzyń P, Pyrkowska A, Duda MK, Bedziarski T, Mazczewski M, Langfort J, Dobrzyń A. Expression of lipogenic genes is upregulated in the heart with exercise training-induced but not pressure overload-induced left ventricular hypertrophy. Am J Physiol Endocrinol Metab 2013;304:E1348-58.

13. Xue L, Chen W, Ma M, Chen A, Tang C, Zhang C, Cai L. Microarray profiling analysis identifies the mechanism of miR-200b-3p/mRNA-CD36 affecting diabetic cardiomyopathy via peroxisome proliferator activated receptor-γ signaling pathway. J Cell Biochem 2019;120:5193-5206.

14. Andersen M, Lenhard B, Whitting C, Eriksson P, Oberg J. Alternative promoter usage of the membrane glycoprotein CD36. BMC Mol Biol 2006;7:8.

15. Hall D, Mayosi BM, Rahman TJ, Avery PJ, Watkins HC, Keaveny B. Common variation in the CD36 (fatty acid translocase) gene is associated with left-ventricular mass. J Hypertens 2011;29:690-695.

16. Jayawardene AF, Gwinn T, Hancock DP, Mavros Y, Rooney KB. The associations between polymorphism in the CD36 gene, fat oxidation and cardiovascular disease risk factors in a young adult Japanese population: a pilot study. Obes Res Int 2014;2014:e18-21-e621.

17. Zhang Y, Ling ZY, Deng SB, Du HA, Yin HY, Yuan J, She Q, Chen YQ. Associations between CD36 gene polymorphisms and susceptibility to coronary artery heart disease. Braz J Med Biol Res 2014;47:895-903.

18. Che J, Zhao XY, Li GP. Association between rs1049673 polymorphism in CD36 and premature coronary heart disease. Gene Mol Biol 2014;37:7708–7717.

19. Du Y, Chen K, Liu E, Wang X, Li F, Liu T, Zheng X, Li G, Che J. Gender-specific associations of CD36 polymorphisms with the lipid profile and susceptibility to premature multi-vascular coronary artery heart disease in the Northern Han Chinese. Gene 2020;753:144806.

20. Love-Gregory L, Sherva S, Renna L, Wasson J, Schappe T, Doria A, Rao DC, Hunt SC, Klein S, Neuman PJ, Permutt MA, Abumrad NA. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet 2008;17:1695-1704.

21. Abdurrah NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding of transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36, SR-BI and CD36. Biochim Biophys Acta 1993;1172:285-290.

22. Gervais DE, Lipsky PE. Odenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transmembrane function. Blood 1992;80:1053-1115.

23. Neculai D, Schwake M, Ravichandran M, Zunke F, Collins RF, Peters J, Neculai M, Plumb J, Loppnow P, Pizarro JRC, Seitaov A, Trimble WS, Safit P, Grinshtein S, Dhe-Paganon S. Structure of LMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013;504:172-176.

24. Pepino MY, Koda S, Osmovski D, Abdurrah NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Ann Rev Nutr 2014;34:281-303.

25. Gomez-Diaz C, Bargeton B, Abulin B, Bukar N, Reina JH, Bartoi T, Graf M, Ong H, Ulrich PHT, Masson J-F, Benton R. A CD36 ectodomain mediates innate phagocyte detection via a unique phagocytic tunneling mechanism. Nat Commun 2016;7:11886.

26. Glatz JFC, Nabben M, Heeschen LC, Boren A, Luiken JFP. Regulation of the subcellular trafficking of CD36, a major determinant of fatty acid utilization. Biochim Biophys Acta 2016;1861:1461–1471.

27. Samovski D, Dhule P, Pietka T, Jacome-Sosa M, Penrose E, Son NH, Flynn CR, Shoghi KL, Hyrc KG, Goldberg IJ, Gamanzon ER, Abdurrah NA. Regulation of insulin receptor pathway and glucose metabolism by CD36 signaling. Diabetes 2016;65:1217-1228.

28. Monaco C, Whitfield J, Jain SS, Spriet LL, Boren A, Holloway GW. Activation of adipokine α2 is not required for mitochondrial fat/c36 accumulation during exercise. PLoS One 2015;10:e0126122.

29. Chanda D, Luiken JFP, Glatz JFC. Signaling pathways involved in cardiac energy metabolism. FEBS Lett 2016;590:2364–2374.

30. Samovski D, Su X, Xu Y, Nawab NA, Stahl PD. Insulin and AMPK regulate FA translocase/CD36 plasma membrane recruitment in cardiomyocytes via Rab GAP AS160 and Rabba-Rab GTPase. J Lipid Res 2012;53:709-717.

31. Luiken JFP, Dyck JD, Han X-X, Tandon NN, Arnugam Y, Glatz JFC, Boren A. Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am J Physiol Endocrinol Metab 2002;282:E491-5.
56. Luiken JJFP, Owuens DM, Habets DDJ, van der Zon GCM, Coumans WA, Schwenger RW, Bonen A, Glatz JFC. Permissive action of protein kinase C-ε in insulin-insensitive murine cardiac myocytes. J Endocrinol 2009; 201:199–209.

57. Luiken JJFP, Nabben M, Neumann D, Glatz JFC. Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance. Biochim Biophys Acta Mol Basis Dis 2020;1866:16575.

58. Schwenger RW, Dirx H, Coumans WA, Bonen A, Klip A, Glatz JFC. Luiken JJFP. Requirement for distinct palmitate-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia 2010;53:2209–2219.

59. Rose AJ, Jeppesen J, Kiens B, Richter EA. Effects of contraction on localization of GLUT4 and v-SNARE isoforms in rat skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2009; 297:R1228–37.

60. Luiken JJFP, Coorl S, Bonen DPY, van der Horst DJ, Bonen A, Zorsano A, Glatz JFC. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch – Eur J Physiol 2004;448:1–15.

61. Luiken JJFP, Coorl SML, Willems J, Coumans WA, Bonen A, van der Vusse GJ, Glatz JFC. Contractinduction of fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003;52:1635–1643.

62. Samovski D, Sun J, Petka T, Gross RW, Eckel RH, Su X, Stahl PD, Abumrad NA. Regulation of AMPK activation by CD36 links fatty acid uptake to β-oxidation. Diabetes 2015;64:353–359.

63. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med 2014; 20:1242–1253.

64. Abumrad NA, Moore DJ. Parkin reverts itself to regulate fatty acid metabolism by targeting PPAR-α. J Clin Invest 2011;121:3899–3902.

65. Kim K-Y, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer WA. Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their essentiality for insulin- or AMP-activated protein kinase-induced CD36 translocation. Arch Biochem Biophys 2014;120:40–49.

66. Zhang F, Xia X, Chai R, Xu R, Xu Q, Liu M, Chen X, Liu B, Liu S, Liu N. Inhibition of USP14 suppresses the formation of cell body by promoting CD36 degradation. J Cell Physiol 2020;234:3392–3402.

67. Tran TT, Poirier H, Clement L, Nassir F, Peisers MMP, Petit V, Degraeve P, Monnot M-C, Glatz JFC, Abumrad NA, Besnard P, Niot I. Linalipid regulates CD36 levels and downstream signaling to stimulate chylomycin synthesis. J Biol Chem 2011;286:25201–25210.

68. Smith J, Su X, El-Maghrabi R, Stahl PD, Abumrad NA. Opposite regulation of CD66 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem 2008;283:13578–13585.

69. Sun S, Tan P, Huang X, Zhang W, Kong C, Ren F, Su X. Ubiquitinated CD66 sustains insulin-stimulated Akt activation by stabilizing insulin receptor substrate 1 in myotubes. J Biol Chem 2018;293:2383–2394.

70. Srinanthan S, Li W, Silverstein RL, Mchture TM. Eososome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions. Platelets 2014;25:109–116.

71. Ho M, Hoang HL, Lee KM, Liu N, MacRae T, Voorn D, Youle RJ, Amar M, Remaley AT, Sack SN, Berger RH. Biochim Biophys Acta Mol Basis Dis 2011;1803:40–49.

72. Ho M, Hoang HL, Lee KM, Liu N, MacRae T, Van Doorn JM, Kerner J, Van Der Horst DJ, Luiken JJFP, Rodenburg KGW. Each of the four intracellular cysteines of CD66 is essential for insulin- or AMP-activated protein kinase-induced CD36 translocation. Arch Biochem Biophys 2012;410:346–51.

73. Lejay A, Fay J, Feng R, van JAD, Barr M, Thaveau F, Chaike F, Geny B, Scholey JW. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol 2016;91:11–22.

74. Lesniewski EJ, Chen Q, Tandier B, Hoppel CL. Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies. Annu Rev Pharmacol Toxicol 2017;57:335–365.

75. Heathert LC, Pates KM, Atherton HJ, Cole MA, Ball DR, Evans RD, Gratz JF, Luiken JJFP, Griffin JL, Clarke K. Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. Circ Res 2013;112:1058–1066.

76. Steinbusch LKM, Wijnen W, Schwenk RW, Coumans WA, Hoebers NTH, Owuens DM, Coumans WA, Hoebers NTH, Diamant M, Bonen A, Gratz JFC, Luiken JJFP. Differential regulation of cardiac glucose and fatty acid uptake by endosomal pH and actin filaments. Am J Physiol Cell Physiol 2010;298:C1549–59.

77. Fukushima A, Milner K, Gupta A, Lopachuk GD. Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets. Curr Pharm Des 2015;21:3654–3664.

78. Umaraswamy Y, Syamasundar MRAA, Kotabashi N, Yamaguchi A, Hanako H, Hishiki T, Nagahata-Naito Y, Obinata H, Sano M, Sunaga H, Matsu H, Tsuchiya Y, Suematsu M, Kuraiyashi M, Iso T. Glucose is preferentially utilized for biomass synthesis in pressure-overloaded hearts: evidence from fatty acid-binding protein-4 and -5 knockout mice. Cardiovasc Res 2018;111:1132–1144.

79. Jelink J, Togiel U, Alvarez-Hernandez E, Schoiber D, Zweck E, Ding Z, Rothme M, Mastrototaro L, Kohlhaas V, Kotzka J, Krebel B, Muller-Wieland D, Moellendorf S, Godicke A, Kelm M, Westerfeld R, Roden M, Szendroedi J. Insulin resistance and vulnerability to cardiac ischemia. Diabetes 2018;67:2695–2702.

80. Liu Y, Neumann D, Glatz JFC, Luiken JJFP. Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction. Prostaglandins Leukot Essent Fatty Acids 2010;81:131–141.

81. Lefevre M, Valleron A, Vidal J, Cardin P, Kien A, Behr M. AMPK regulates palmitic acid-induced apoptosis and lipid accumulation in cardiomyocytes. Lipids 2017;52:737–750.

82. Gentek R, Hoefell G. The innate immune response in myocardial infarction, repair, and regeneration. Adv Exp Med Biol 2017;1003:251–272.

83. Weinberger T, Schul C. Myocardial infarction: a critical role of macrophages in cardiac remodeling. Front Physiol 2015;6:167.

84. Dehn S, Thorpe EB. Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nrf41-dependent mechanisms of cardiac repair. FASEB J 2018;32:254–264.

85. DeLeon-Pennell KY, Tian Y, Zhang B, Cates CA, Iyer RP, Cannon PL, Shah P, Ayetan P, Halade GV, Ma Y, Flynn E, Zhang J, Yin Y-F, Zhang H, Lindsey ML. CD36 is a matrix metalloproteinase-9 substrate that stimulates neutrophil apoptosis and removal during postcardiac remodeling. Circ Res 2016;118:14–25.

86. Lindsey ML, Jung M, Yabluchanskiy A, Cannon PL, Iyer RP, Flynn ER, DeLeon-Pennell KY, Valiero FM, Harrison CL, Rippinger CM, Hall MA, Me Y. Exogenous CCX41 infusion inhibits macrophage phagocytosis by limiting CD36 signaling to enhance postmyocardial infarction cardiac dilation and mortality. Cardiovasc Res 2019;115:395–408.

87. Greenwalt DE, Scheck SH, Rheinfarter-Jones T. Heart CD36 expression is increased in insulin resistant models of diabetes and in mice fed a high fat diet. J Clin Invest 1993;92:1388–1388.

88. Pinto AR, Ilyinik A, Ivey M, Kuwabara JT, D’Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, Tallquist MD. Revisiting cardiac cellular composition. Circ Res 2016;118:400–409.

89. Coorl SML, Willems J, Coumans WA, van der Vusse GJ, Bonen A, Glatz JFC, Luiken JJFP. Sulfonamides inhibit esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 2002;239:213–219.

90. Mansor LS, Sousa Filho M, da L, Yea G, Coumans WA, West JA, Kerr M, Carr CA, Luiken JJFP, Glatz JFC, Evans RD, Griffin J, Tyler DJ. Clarke K, Heather LC.
Inhibition of sarcolemmal FAT/CD36 by siltorn-succinimidyloleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/exoxygenation. Cardiovasc Res 2010;88:737–748.

105. Marleau S, Harb D, Bujold J, Avalone R, Iken K, Wang Y, Demers A, Sirois MG, Marleau S, Harb D, Bujold J, Avalone R, Iken K, Wang Y, Demers A, Sirois MG, Canley AN, Severson DL. What are the biochemical mechanisms responsible for peroxisomopathy? Cell Metab 2017;26:34–45.

114. Joubert M, Manrique A, Cariou B, Prieur X. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways. J Diabetes Res 2016;2016:473–480.

146. Santos MHH, Higuchi M, de L, Tucci PJF, Garavelo SM, Reis MM, Antonio EL, Serra ~Ao RC. Previous exercise training increases levels of PPAR-α in long-term post-myocardial infarction in rats, which is correlated with better inflammatory response. Clinics (Sao Paulo) 2015;70:163–168.

152. van der Meer DLM, Degenhardt T, Vaisanen S, de Groot PJ, Heinarinen M, de Vries DW. Nuclear mir-320 mediates diabetes-induced cardiac dysfunction by activating mapk pathway after ischaemia/reperfusion injury in a rat heart. Lung Heart Circ 2017;26:404–412.

153. He C, Zhang G, Ouyang H, Zhang P, Chen Y, Wang R, Zhou H. Effects of exercise in mice. J Mol Cell Cardiol 2013;53:1655–1663.

156. Santos MHH, Higuchi M, de L, Tucci PJF, Garavelo SM, Reis MM, Antonio EL, Serra ~Ao RC. Previous exercise training increases levels of PPAR-α in long-term post-myocardial infarction in rats, which is correlated with better inflammatory response. Clinics (Sao Paulo) 2015;70:163–168.

CD36 in Cardiovascular Diseases
153. Bekkering S, Quintin J, Joosten LAB, van der Meer JWM, Netea MG, Riksen NP. Hamidzadeh K, Christensen SM, Dalby E, Chandrasekaran P, Mosser DM.

154. Chen Y, Yang M, Huang W, Chen W, Zhao Y, Schulte ML, Volberding P, Gerbec Z, H. Shu

157. Glatz JFC, Nabben M, Young ME, Schulze PC, Taegtmeyer H, Luiken JJFP. Re-balancing cellular energy substrate metabolism to mend the failing heart. Biochem Biophys Acta Mol Basis Dis 2020;1866:156579.

158. Nakata K, Masuoka T, Saito M, Zhu Y, Okada T, Naito AT, Ohama T, Koseki M, Ota T, Akazawa H, Nishida M, Komuro I, Sakata Y, Yamashita S. Pressure overload impairs cardiac function in long-chain fatty acid transporter CD36 knockout mice. Int Heart J 2019;60:159–167.

159. Umbarawan Y, Samsunnamo MRAA, Kanahara H, Hishiki T, Hayakawa N, Sano M, Sunaga H, Matsui H, Tsuchima Y, Sugiyama M, Kurasabayashi M, Isotani T. Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure. Sci Rep 2018;8:12035.

160. Zhu Y, Xian X, Wang Z, B. Chen Q, Han X, Tang D, Chen R. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules 2018;8:80.

162. Li C, Cai C, Zheng X, Sun J, Ye L. Orientin suppresses oxidized low-density lipoprotein-induced inflammation and oxidative stress of macrophages. Biochim Biophys Acta 2020;1847:774–779.

163. Sato Y, Watanabe T, Lohraya N, Ozawa N, Takahashi Y, Shirai S, Kato M, Mori Y, Matsuura T, Ishibashi-Ueda H, Hiranou T, Watanabe T. Inhibitory effects of vosostatin-1 against atherogenesis. Clin Sci (Lond) 2018;132:2493–2507.

164. Nagy L, Tontonoz P, Alberga J, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93:229–240.

165. Zhou M-S, Chadipiralla K, Mendez AJ, Jaimes EA, Silverstein RL, Webster K, Raij L. Metabolic reprogramming by CD36 signaling drives macrophage inflammatory responses and atherosclerosis. J Clin Invest 2018;128:1401–1438.

166. Liu S, Li D, Han H, Qian Y, Feng L, Wu Z, Wang F, Feng J, Yang D, Qin Z, Yan X. Macrophage CD146 promotes foam cell formation and retention during atherosclerosis. Cell Res 2017;27:352–372.

167. Park YM, Feibraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 2009;119:136–145.

168. Xu S, Li J, Yang Y, He H, Shao C, Sun Z, Bao D, Z. Zhu J, Jing L, Wang Z. CD66 accelerates atherosclerotic progression via inhibiting foam cell migration. BioMed Pharmacother 2018;99:1020–1030.

169. Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Feibraio M, Anselmo RM, Marchant K, Barnard J, Silverstein RL. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood 2011;117:635–6366.

170. Lee K, Lin K-H, Hu C-Y, Lo S-C. Thromboelastography characterized CD36 null subjects as slow clot formation and indicative of hypocoagulability. Thromb Res 2019;178:79–84.

171. Wilhelmsen P, Kjaer J, Thomsen KL, Nielsen CT, Dige A, Maniecki MB, Heegaard N, Granbæk H, Dahløper J, Handberg A. Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. Arch Physiol Biochem 2011;119:202–208.

172. Podrez EA, Byzova TV, Feibraio M, Salomon RG, Ma Y, Vaiyavaseetil M, Poliakov E, Sun M, Finton J, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13:1086–1095.

173. Nergiz-Ural R, Lamers MME, Van Kruchten R, Luiken J, Cozermans JM, Ghaz IJFC, Kuipers MJ, Meerskem JHM. Signaling role of CD36 in platelet activation and atherosclerotic formation by immobilized thrombospin or oxidized low-density lipoprotein. J Thromb Haemost 2019;17:1835–1846.

174. Yang M, Cooley BC, Li W, Chen Y, Vaszquez-Vivar J, Scoggins NO, Cameron SJ, Morrell CN, Silverstein RL. Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions. Blood 2017;129:2917–2927.

175. Ghosh A, Li W, Feibraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombus in mice. J Clin Invest 2008;118:1934–1943.

176. Bao Y, Wang L, Xu Y, Yang Y, Wang L, Si S, Cho S, Hong B. Salvanolic acid B inhibits its macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner. Atherosclerosis 2012;223:152–159.

177. Wu T, Peng Y, Yan S, Li N, Chen Y, Tan L. Andrographolide ameliorates atherosclerosis by suppressing pro-inflammation and ROS generation-mediated foam cell formation. Inflammation 2018;41:1681–1689.

178. Yu M, Jiang M, Chen Y, Zhang S, Zhang W, Yang X, Li X, Li Y, Duan S, Han J, Duan Y. Inhibition of macrophage CD36 expression and cellular oxidized low density lipoprotein (oxLDL) accumulation by tamoxifen: a peroxisome proliferator-activator receptor (PPAR)γ-dependent mechanism. J Biol Chem 2016;291:16977–16989.

179. Yao S, Tian H, Miao C, Zhang D-W, Zhao L, Li Y, Yang N, Jiao P, Sang H, Guo S, Wang Y, Qin S. D4f alleviates macrophage-derived foam cell apoptosis by inhibiting CD36 expression and ER stress-CHOP pathway. J Lipid Res 2015;56:836–847.

180. Dai X-Y, Cai Y, Sun W, Ding Y, Wang W, Kong W, Tang C, Zhu Y, Xu MJ, Wang X. Intermedin inhibits macrophage foam-cell formation via tristetraprolin-mediated decay of CD36 mRNA. Cardiovasc Res 2014;101:297–305.

181. Zhang J, Nies S, Martinez-Zagualin R, Sennoure SR, Wang S. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. J Nutr Biochem 2016;30:14–23.

182. Zhou M, Wang H, Zeng Y, Yin P, Zhu J, Chen W, Li X, Wang L, Liu Y, Liu J, Zhang M, Ji Q, Yu S, Ashin A, Galidou E, Glenn S, Krish VS, Miller-Petrie MK, Morrell-Jennings WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet (Lond) Engl 2019;394:1145–1158.

183. D’Souza K, Naziroor C, Keneberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochm Biophys Acta 2015;1861:1513–1524.

184. Park T-S, Yamashita H, Blaser WS, Goldberg J. Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 2007;18:277–282.

185. Evans RD, Hauthon D. The role of triacylglycerol in cardiac energy provision. Biochm Biophys Acta 2016;1861:1481–1491.

186. Bjorkgren J, Véniant M, Kim SK, Withycombe SK, Wood PA, Hellerstein MK, Neese RA, Young SG. Hepatocyte secretion and triglyceride stores in the heart. J Biol Chem 2001;276:38511–38517.

187. Heier C, Haemmerle G. Fat in the heart: the enzymatic machinery regulating cardiac triacylglycerol metabolism. Biochm Biophys Acta 2016;1861:1500–1512.

188. Chung W, Wu P, Du Y, Wang Y, Zhou N, Ge Y, Yang Z. Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction. Biochem Biophys Res Commun 2015;463:1108–1114.
201. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJFP, Glatz JFC, Bonen A. A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 2004;279:36235–36241.

202. Bezaire V, Bruce CR, Heigenhauser GJF, Tandon NN, Glatz JFC, Luiken JJFP, Bonen A, Spriet LL. Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: essential role in fatty acid oxidation. Am J Physiol Endocrinol Metab 2006;290:E509–15.

203. Steinbusch LKM, Schwenk RW, Ouwens DM, Diamant M, Glatz JFC, Luiken JJFP. Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci 2011;68:2525–2538.

204. Luiken JJFP, Coort SLM, Koonen DPY, Bonen A, Glatz JFC. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes. Proc Nutr Soc 2004;63:251–258.

205. Zhao L, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. CD36 and lipid metabolism in the evolution of atherosclerosis. Br Med Bull 2018;126:101–112.

206. Choromańska B, Myśliwiec P, Choromańska K, Dadan J, Chabowski A. The role of CD36 receptor in the pathogenesis of atherosclerosis. Adv Clin Exp Med 2017;26:717–722.